Immune profile for successful cancer immunotherapy discovered
Share

In a new study published online June 25, 2018 in Nature Medicine, UC San Francisco researchers have identified a key biological pathway in human cancer patients that appears to prime the immune system for a successful response to immunotherapy drugs known as checkpoint inhibitors. The findings, including initial observations from human tumor samples, mechanistic studies in mouse models, then confirmation in additional patient samples, could better enable clinicians to predict which patients will naturally benefit from these promising new treatments, and potentially to modify the immune response in other patients to allow more people to benefit from these therapies.

Nature Medicine

Cancers are often able to evade the immune system by activating the “brakes” built into T cells that normally prevent them from attacking the body’s own tissues. By cutting these brakes, checkpoint inhibitor drugs can “wake up” the immune system to the threat of these cancers and has successfully eliminated malignancies in about 20-40 percent of patients with melanoma and certain other cancer types. In the best cases, awakened T cells continue to patrol the body and prevent the cancer from ever coming back. But in the majority of patients, immunotherapies fail to have their intended effect — even with their

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD